Cargando…

VISTA: A Promising Target for Cancer Immunotherapy?

Agents targeting the B7 family co-inhibitory receptors cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein-1 (PD-1), or its ligand (PD-L1), have a pivotal role in clinical practice. V-domain Ig suppressor of T-cell activation (VISTA) is a protein highly conserved between spec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tagliamento, Marco, Agostinetto, Elisa, Borea, Roberto, Brandão, Mariana, Poggio, Francesca, Addeo, Alfredo, Lambertini, Matteo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235942/ https://www.ncbi.nlm.nih.gov/pubmed/34189130 http://dx.doi.org/10.2147/ITT.S260429

Ejemplares similares

New emerging targets in cancer immunotherapy: the role of VISTA
por: Tagliamento, Marco, et al.
Publicado: (2020)

VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy
por: Shekari, Najibeh, et al.
Publicado: (2023)

VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy
por: Yuan, Long, et al.
Publicado: (2021)

Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis
por: Tagliamento, Marco, et al.
Publicado: (2021)

IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy
por: Tang, Xi-Yang, et al.
Publicado: (2022)

Update on the Management of Breast Cancer during Pregnancy
por: Poggio, Francesca, et al.
Publicado: (2020)

Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer
por: Parisi, Francesca, et al.
Publicado: (2020)

Neoadjuvant Immunotherapy: A Promising New Standard of Care
por: Boydell, Emma, et al.
Publicado: (2023)

Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis
por: Poggio, Francesca, et al.
Publicado: (2018)

New emerging targets in cancer immunotherapy: the role of TIM3
por: Friedlaender, Alex, et al.
Publicado: (2019)

Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
por: Agostinetto, Elisa, et al.
Publicado: (2023)

Terminating Cancer by Blocking VISTA as a Novel Immunotherapy: Hasta la vista, baby
por: Yum, Ji-Eun Irene, et al.
Publicado: (2021)

Call for ensuring cancer care continuity during COVID-19 pandemic
por: Tagliamento, Marco, et al.
Publicado: (2020)

Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy
por: Hong, Shanjuan, et al.
Publicado: (2019)

ESMO Open special series on new emerging targets in cancer immunotherapy
por: Lambertini, Matteo
Publicado: (2020)

VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy
por: Huang, Xing, et al.
Publicado: (2020)

Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer
por: Jacobs, Flavia, et al.
Publicado: (2023)

Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?
por: Poggio, Francesca, et al.
Publicado: (2018)

TIM-3, a promising target for cancer immunotherapy
por: He, Yayi, et al.
Publicado: (2018)

Pleural Mesothelioma in the Era of Immunotherapy
por: Chevallier, Mathieu, et al.
Publicado: (2023)

The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy
por: Banna, Giuseppe Luigi, et al.
Publicado: (2019)

Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer
por: Zheng, Yue, et al.
Publicado: (2022)

VISTA in Soft Tissue Sarcomas: A Perspective for Immunotherapy?
por: Albertsmeier, Markus, et al.
Publicado: (2022)

VISTA Is a Diagnostic Biomarker and Immunotherapy Target of Aggressive Feline Mammary Carcinoma Subtypes
por: Gameiro, Andreia, et al.
Publicado: (2021)

Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy
por: Wu, Huai-liang, et al.
Publicado: (2022)

MHC Phosphopeptides: Promising Targets for Immunotherapy of Cancer and Other Chronic Diseases
por: Mahoney, Keira E., et al.
Publicado: (2021)

Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women
por: Martelli, Valentino, et al.
Publicado: (2021)

Burning Questions in the Oncofertility Counseling of Young Breast Cancer Patients
por: Arecco, Luca, et al.
Publicado: (2020)

Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis
por: Becerril-Gaitan, Andrea, et al.
Publicado: (2022)

Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives
por: Agostinetto, Elisa, et al.
Publicado: (2022)

Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy
por: Niu, Xiaoshuang, et al.
Publicado: (2023)

Vista of the Future: Novel Immunotherapy Based on the Human V-Set Immunoregulatory Receptor for Digestive System Tumors
por: Chmiel, Paulina, et al.
Publicado: (2023)

Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies
por: Saini, Kamal S., et al.
Publicado: (2020)

Management of young women with early breast cancer
por: Poggio, Francesca, et al.
Publicado: (2018)

Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma
por: Cho, Shih-Feng, et al.
Publicado: (2021)

Lung cancer immunotherapy: progress, pitfalls, and promises
por: Lahiri, Aritraa, et al.
Publicado: (2023)

Dickkopf-1: A Promising Target for Cancer Immunotherapy
por: Chu, Hang Yin, et al.
Publicado: (2021)

Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways
por: Li, Kai, et al.
Publicado: (2017)

TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors
por: Sauer, Natalia, et al.
Publicado: (2023)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a86tnegc8kamb8ug1apdeujmqs